FluoGuide annonces publication of two patent applications covering the company’s uPAR technology platform for improving surgery
Copenhagen, Denmark, 2 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that two new patent applications, covering the use of uPAR in enhancing surgical precision by illuminating cancer cells, have been published.FluoGuide hereby updates on the status of its published patents and patent applications. Since prior to the IPO, FluoGuide holds the patent family (WO2016041558), relating to the Company’s lead compound FG001. FG001 is designed to allow surgeons to clearly delineate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology